Queyrat Disease – Comprehensive Medical Guide

Overview

Queyrat disease is a rare form of intra‑epithelial squamous cell carcinoma (also called carcinoma in situ) that occurs on the glans penis or the pre‑putial skin. It presents as a persistent, velvety, erythematous patch that does not resolve with typical treatments for eczema or fungal infection. Because it is a pre‑cancerous lesion, early recognition and treatment are critical.

• Age group: Most commonly diagnosed in men aged 50–70 years, although cases have been reported in younger adults.
• Prevalence: Exact incidence is unclear due to its rarity; estimates suggest < 1 case per 100,000 men per year in the United States (CDC, 2022).
• Geography: Higher rates are reported in regions with a higher prevalence of human papillomavirus (HPV) infection and lower circumcision rates (e.g., parts of Africa, Asia, and certain European countries).

Queyrat disease is named after the French dermatologist Henri Queyrat, who first described the condition in 1902. It belongs to the spectrum of penile intra‑epithelial neoplasia (PeIN), and if left untreated it can progress to invasive penile squamous cell carcinoma.

Symptoms

The condition often begins subtly, which can lead to delays in diagnosis. Common presenting features include:

• Persistent erythema: A well‑defined, bright‑red or pink patch on the glans or inner foreskin that does not blanch with pressure.
• Velvety or smooth texture: The surface feels soft and “velvety” rather than rough or scaly.
• Fine, superficial ulcerations: Small, painless erosions may appear within the patch.
• Itching or mild burning: Sensations range from mild pruritus to a burning feeling, especially after friction.
• Absence of discharge: Unlike infectious balanitis, there is typically no purulent or foul‑smelling discharge.
• Bleeding on minor trauma: The area may bleed easily when rubbed or during intercourse.
• No systemic symptoms: Fever, weight loss, or lymphadenopathy are rare unless invasive cancer develops.

Because these signs may mimic benign dermatologic conditions (eczema, psoriasis, lichen planus), a biopsy is essential for definitive diagnosis.

Causes and Risk Factors

Queyrat disease is a form of carcinoma in situ, meaning that it arises from genetic changes that transform normal squamous cells into pre‑cancerous cells.

Primary etiologic factors

• Human papillomavirus (HPV) infection: High‑risk subtypes, especially HPV‑16 and HPV‑18, are detected in up to 70 % of lesions (NIH, 2021).
• Chronic irritation: Poor genital hygiene, chronic balanitis, or persistent friction from tight clothing can promote cellular dysplasia.
• Phimosis: Inability to retract the foreskin creates a moist environment conducive to HPV persistence.
• Immunosuppression: HIV infection, organ transplantation, or long‑term corticosteroid use increase risk.

Additional risk factors

• Age > 50 years
• Uncircumcised status (particularly in regions without routine neonatal circumcision)
• History of other genital or cutaneous HPV‑related lesions (e.g., condyloma acuminata)
• Smoking – tobacco carcinogens may act synergistically with HPV.
• Previous penile intra‑epithelial neoplasia or penile cancer.

Diagnosis

Accurate diagnosis requires a combination of clinical assessment and histopathologic confirmation.

Clinical examination

• Visual inspection of the genitalia under good lighting.
• Use of a dermatoscope can highlight vascular patterns typical of carcinoma in situ.
• Palpation of regional lymph nodes (inguinal) to assess for enlargement.

Biopsy

The gold‑standard test. Two main techniques are used:

1. Punch biopsy: A 4‑mm circular instrument removes a full‑thickness skin sample.
2. Incisional/excisional biopsy: Larger lesions may require a wedge or complete excision for thorough evaluation.

Histology shows full‑thickness atypia of squamous cells without invasion of the basement membrane, confirming carcinoma in situ.

Adjunctive tests

• HPV DNA testing: PCR on the biopsy specimen identifies high‑risk subtypes.
• Imaging (ultrasound or MRI): Reserved for cases where invasion is suspected or when lymphadenopathy is present.
• Serology for HIV: Recommended for all patients with Queyrat disease due to the strong association with immunosuppression.

Treatment Options

Management aims to eradicate the lesion, preserve penile function, and prevent progression to invasive cancer. Choice of therapy depends on lesion size, location, patient comorbidities, and personal preference.

Topical therapies

• 5‑Fluorouracil (5‑FU) cream 5 %: Applied twice daily for 4–6 weeks. Causes local inflammation that destroys dysplastic cells. Cure rates 70‑80 % (Cleveland Clinic, 2023).
• Imiquimod 5 % cream: An immune response modifier applied 3 times weekly for 12–16 weeks. Useful for patients who cannot tolerate surgery.
• Diclofenac gel 3 %: Less commonly used; requires 12–16 weeks of twice‑daily application.

Surgical options

• Laser ablation (CO₂ or Nd:YAG): Precise removal of the lesion with minimal blood loss. Recurrence rates 10‑20 %.
• Electrosurgical excision (curettage & electrodesiccation): Effective for small (<2 cm) lesions.
• Partial glansectomy or circumcision: Indicated when the lesion involves the foreskin or when there is concurrent phimosis.

Radiation therapy

Reserved for patients who are not surgical candidates. Low‑dose external beam radiation yields 80 % local control but carries risk of urethral stenosis.

Systemic therapy

Not routinely used for isolated Queyrat disease, but in extensive or recurrent cases, systemic retinoids (e.g., acitretin) have been described.

Lifestyle & supportive measures

• Smoking cessation.
• Improved genital hygiene – gentle washing with mild soap and thorough drying.
• Regular self‑examination after treatment to detect early recurrence.

Living with Queyrat Disease

Even after successful treatment, ongoing vigilance is essential.

• Self‑inspection: Examine the glans and foreskin weekly; note any new redness, ulceration, or changes.
• Follow‑up schedule: Dermatology or urology visits every 3–6 months for the first two years, then annually.
• Sexual health: Use condoms to reduce HPV transmission; discuss HPV vaccination with your partner.
• Pain management: Over‑the‑counter analgesics (acetaminophen or ibuprofen) can relieve post‑procedure discomfort.
• Psychological support: The location of the lesion can cause anxiety or body‑image concerns. Counseling or support groups can be beneficial.

Prevention

Because HPV infection is a central factor, many preventive strategies target viral transmission and chronic irritation.

• HPV vaccination: The 9‑valent vaccine (Gardasil 9) protects against HPV‑16/18 and is recommended for males up to age 26, and for some men up to age 45.
• Circumcision: Neonatal circumcision reduces the risk of penile intra‑epithelial neoplasia by up to 70 % (WHO, 2020).
• Safe sexual practices: Consistent condom use lowers HPV exposure.
• Smoking cessation: Reduces overall carcinogenic burden.
• Good genital hygiene: Daily cleaning, especially in uncircumcised men, prevents chronic inflammation.
• Regular medical check‑ups: Early detection of premalignant lesions improves outcomes.

Complications

If untreated, Queyrat disease can progress or cause secondary issues.

• Invasive penile squamous cell carcinoma: Reported progression in 5‑10 % of untreated cases over 5 years (Mayo Clinic, 2022).
• Urethral stricture: Chronic inflammation or repeated procedures may scar the urethra, causing narrowing and urinary difficulty.
• Psychosexual impact: Pain, embarrassment, and fear of cancer can affect sexual activity and relationships.
• Local infection: Ulcerated lesions may become secondarily infected.
• Recurrence: Up to 30 % of patients experience a recurrent lesion within 2 years, emphasizing the need for surveillance.

When to Seek Emergency Care

References

• Mayo Clinic. “Penile cancer.” Updated 2022. https://www.mayoclinic.org
• Centers for Disease Control and Prevention (CDC). “HPV and Cancer.” 2022. https://www.cdc.gov
• National Institutes of Health (NIH). “Human Papillomavirus (HPV) Infections.” 2021. https://www.nih.gov
• World Health Organization (WHO). “Male circumcision and health outcomes.” 2020. https://www.who.int
• Cleveland Clinic. “Carcinoma in situ of the penis (Queyrat disease).” 2023. https://my.clevelandclinic.org
• American Cancer Society. “Penile cancer treatment (adult)”. 2023. https://www.cancer.org